BioNTech acquiring MAB Discovery's antibody generation unit

BioNTech AG (Mainz, Germany) will acquire the antibody generation unit of MAB Discovery GmbH (Neuried, Germany) to expand its capabilities to rapidly produce new mAb candidates.

BioNTech will gain all of MAB Discovery's assets, employees and IP regarding mAb generation. MAB Discovery will retain its preclinical pipeline of immuno-oncology antibodies. Financial terms were not disclosed...